Spyre Therapeutics shared promising Phase 2 trial results for its antibody treatments targeting inflammatory bowel disease (IBD), including ulcerative colitis. The data showed early clinical proof of concept for three antibodies, with combination therapy results expected in 2027. UBS initiated coverage with a Buy rating and set a $120 price target, highlighting Spyre's potential in IBD treatment. Despite a net loss in Q2 2026, Spyre's research progress and strategic outlook have attracted positive analyst attention.
Spyre Therapeutics (SYRE) is trading at USD 79.90 with no change in the last day as of Oct 19, 2026 20:14 WIB on Pluang. The stock holds a market cap of $7.47 billion and an enterprise value of $6.47 billion, reflecting steady investor interest despite the company's recent net loss. UBS's Buy rating and $120 price target highlight optimism about Spyre's IBD treatment potential, aligning with the platform's stable trading activity.
